
CVSA Stock Forecast & Price Target
CVSA Analyst Ratings
Bulls say
Covista is a leading educator of healthcare professionals, with a diversified portfolio of online and campus-based universities. Despite potential risks from political headwinds and the new loan caps, Covista's strong mix of healthcare-focused programs and favorable supply/demand dynamics make it a top performer in the sector with attractive financials and a solid growth outlook. Although concerns around AI-driven student acquisition and competition from other peers are worth monitoring, Covista's exposure to the growing healthcare field positions it as a more defensive stock for investors seeking long-term stability.
Bears say
Covista is facing a challenging industry backdrop and may struggle to maintain its revenue and EBITDA growth in the near-term. The company's exposure to the GenAI debate in student acquisition may also hinder its potential for multiple expansion. While its revenue and EBITDA projections for FY27 are optimistic, the company's increased CapEx and dilutive margin projections for the near future may limit its profitability. Its recent enrollment growth, particularly in the Chamberlain division, may provide a slight boost to sentiment, but may not be sustainable in the long-term.
This aggregate rating is based on analysts' research of Adtalem Global Education Inc and is not a guaranteed prediction by Public.com or investment advice.
CVSA Analyst Forecast & Price Prediction
Start investing in CVSA
Order type
Buy in
Order amount
Est. shares
0 shares